As senior living developers navigate tighter capital markets, C-PACE (Commercial Property Assessed Clean Energy) financing is emerging as a more prominent tool to help projects move forward.

Rising costs, conservative lending, and thinner margins have made it increasingly difficult to assemble traditional capital stacks. In this environment, C-PACE has shifted from a niche option to a more widely accepted component of project financing.

A new bipartisan proposal in Congress would create some of the clearest federal guardrails yet for kids using AI chatbots, reflecting rising concern about the impact of conversational AI on children’s safety and well-being. According to Axios, the newly introduced CHATBOT Act—sponsored by Sen. Ted Cruz (R-Texas) and Sen. Brian Schatz (D-Hawaii)—would require AI companies to offer “family accounts” for children under 13 that give parents more control over how minors interact with chatbot tools.

The FDA announced on Friday, April 24th that three psychedelic drugs have been granted expedited review vouchers, the first psychedelic treatments to benefit from an executive order signed last week by President Trump easing federal restrictions on psychedelic substances. The FDA granted these initial vouchers to two companies studying the use of psylocibin for treatment-resistant depression and a third company studying methylone (a drug related to MDMA) as a treatment for post-traumatic stress disorder.

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to the growing role of psychedelic research in mental health treatment, addiction care, and veteran health. The order is intended to accelerate research into psychedelic therapies and support faster review of certain investigational treatments already moving through the FDA process.

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to the growing role of psychedelic research in mental health treatment, addiction care, and veteran health. The order is intended to accelerate research into psychedelic therapies and support faster review of certain investigational treatments already moving through the FDA process.

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to the growing role of psychedelic research in mental health treatment, addiction care, and veteran health. The order is intended to accelerate research into psychedelic therapies and support faster review of certain investigational treatments already moving through the FDA process.

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to the growing role of psychedelic research in mental health treatment, addiction care, and veteran health. The order is intended to accelerate research into psychedelic therapies and support faster review of certain investigational treatments already moving through the FDA process.

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to the growing role of psychedelic research in mental health treatment, addiction care, and veteran health. The order is intended to accelerate research into psychedelic therapies and support faster review of certain investigational treatments already moving through the FDA process.

A major change in federal cannabis policy could reshape conversations across healthcare, pharmacy, addiction medicine, and public policy. The U.S. Department of Justice has moved state-licensed medical marijuana from Schedule I to Schedule III, signaling a historic shift in how medical cannabis is regulated at the federal level.